eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Original paper

The relationship between Fc epsilon receptor-1a and b (FCER1A and FCER1B) gene polymorphisms in patients with chronic urticaria using omalizumab

Hulya Savas
1
,
Hatice Uce Ozkol
2
,
Gokhan Gorgisen
3
,
Halil Özkol
4
,
Can Ates
5
,
Ahmet Metin
6
,
İlknur Yorgun Özdemir
2

  1. Department of Dermatology, Erzincan State Hospital, Erzincan, Turkey
  2. Department of Dermatology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  3. Department of Genetics, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  4. Department of Medical Biology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  5. Department of Biostatistics, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  6. Department of Dermatology, Faculty of Medicine, Pamukkale University, Ankara, Turkey
Adv Dermatol Allergol 2024; XLI (4): 357-363
DOI: https://doi.org/10.5114/ada.2024.142285
Online publish date: 2024/08/14
View full text Get citation
 
Introduction:
Chronic urticaria requires well-defined treatment strategies in order to achieve a maximum treatment response and maintain the quality of life. Since 2014, omalizumab has been used in chronic urticaria. However, many studies showed that some patients are resistant to omalizumab.

Aim:
To determine the effects of single nucleotide changes in the FCER1A and FCER1B genes, which are thought to be related to resistance mechanisms, in our population of patients who have not responded to omalizumab treatment.

Material and methods:
We included 100 patients with chronic urticaria who were treated with omalizumab and 50 healthy individuals. Frequently observed gene polymorphisms, FCER1A (rs2251746) and FCER1B (rs569108), were examined in peripheral blood samples. The regions of rs2251746 and rs569108 gene polymorphisms were amplified using fluorescently labelled probes through real-time polymerase chain reaction (PCR). The analysis was performed bioinformatically via the SNP genotype profiling program.

Results:
There was no statistically significant relationship between FCER1A (rs2251746) and FCER1B (rs569108) gene polymorphisms in patients and their clinical, demographic characteristics, and the resistance to treatment (p > 0.05). In our study, the mean patient age was found to be higher in the CT group (44.71 ±12.5 years) compared to the TT group (37.34 ±11.5 years) only in the rs2251746 polymorphism (p < 0.05).

Conclusions:
In our study, there was no significant relationship between FCER1A and FCER1B gene polymorphisms and resistance to omalizumab therapy. Further, multicentre, large-scale studies are needed to support our results.

keywords:

omalizumab, urticaria, genetics, polymorphism, FceRIa, FceRIb
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.